{"id":"autologous-transplantation-using-bexxar-beam","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Secondary malignancy"},{"rate":null,"effect":"Graft failure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BEAM is a myeloablative conditioning regimen that delivers high-dose chemotherapy to eliminate malignant lymphoma cells. Following chemotherapy, autologous hematopoietic stem cells (previously harvested from the patient) are reinfused to restore bone marrow function and immune recovery. Bexxar (tositumomab, an anti-CD20 monoclonal antibody) may be incorporated as part of the conditioning or consolidation strategy to enhance targeting of B-cell lymphomas.","oneSentence":"Bexxar/BEAM is a high-dose chemotherapy regimen (BEAM: carmustine, etoposide, cytarabine, melphalan) followed by autologous stem cell transplantation to treat lymphomas by delivering intensive chemotherapy and restoring bone marrow function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:18.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"},{"name":"Hodgkin lymphoma (as conditioning for autologous transplantation)"}]},"trialDetails":[{"nctId":"NCT00006695","phase":"PHASE2","title":"Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-04-01","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT00329030","phase":"PHASE3","title":"Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-12","conditions":"Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Non-Hodgkin","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tositumomab and Iodine I 131 Tositumomab Bexxar"],"phase":"phase_3","status":"active","brandName":"Autologous transplantation using Bexxar/BEAM","genericName":"Autologous transplantation using Bexxar/BEAM","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bexxar/BEAM is a high-dose chemotherapy regimen (BEAM: carmustine, etoposide, cytarabine, melphalan) followed by autologous stem cell transplantation to treat lymphomas by delivering intensive chemotherapy and restoring bone marrow function. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Hodgkin lymphoma (as conditioning for autologous transplantation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}